Holen Sie sich die Stockscreener-App
231.50
1.76%
4.00
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$227.50
Offen:
$228.42
24-Stunden-Volumen:
8.25M
Relative Volume:
1.28
Marktkapitalisierung:
$409.15B
Einnahmen:
$61.16B
Nettoeinkommen (Verlust:
$4.20B
KGV:
97.80
EPS:
2.3671
Netto-Cashflow:
$19.68B
1W Leistung:
+3.61%
1M Leistung:
+4.87%
6M Leistung:
+14.91%
1J Leistung:
+19.67%
1-Tages-Spanne:
$228.00
$234.74
1-Wochen-Bereich:
$218.05
$234.74
52-Wochen-Spanne:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Firmenname
Abbvie Inc
Sektor
Telefon
(847) 932-7900
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, AZN, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
231.50 | 402.08B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
LLY
Lilly Eli Co
|
1,040.00 | 929.27B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
243.45 | 589.19B | 94.19B | 26.80B | 19.70B | 11.05 |
|
AZN
Astrazeneca Plc
|
205.55 | 317.06B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
163.10 | 307.56B | 54.72B | 14.02B | 15.32B | 7.1855 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-08 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Hochstufung | HSBC Securities | Hold → Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-11-04 | Herabstufung | DZ Bank | Buy → Hold |
| 2025-10-14 | Herabstufung | Erste Group | Buy → Hold |
| 2025-10-01 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-09-17 | Hochstufung | Berenberg | Hold → Buy |
| 2025-08-12 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-04 | Hochstufung | Argus | Hold → Buy |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-12-11 | Hochstufung | Goldman | Neutral → Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-07-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-05 | Herabstufung | Argus | Buy → Hold |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-22 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-11-08 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-08-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Underperform |
| 2022-05-06 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-02-28 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-03 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-03 | Bestätigt | Barclays | Equal Weight |
| 2022-02-03 | Bestätigt | BofA Securities | Neutral |
| 2022-02-03 | Bestätigt | Goldman | Neutral |
| 2022-01-13 | Eingeleitet | Redburn | Buy |
| 2022-01-12 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-11-23 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-23 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Hochstufung | Argus | Hold → Buy |
| 2020-05-18 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Fortgesetzt | Morgan Stanley | Overweight |
| 2020-04-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Bestätigt | Cowen | Outperform |
| 2019-09-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-20 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-04-29 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
Alle ansehen
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
AbbVie stock price climbs again after Botox lawsuit; what ABBV traders watch next - Bez Kabli
AbbVie (NYSE:ABBV) Trading 1.8% HigherTime to Buy? - MarketBeat
AbbVie Inc (ABBV) Shares Up 3% on Feb 13 - GuruFocus
AbbVie Advances New Toxin-Based Therapy in Ventral Hernia Trial: What Investors Should Watch - TipRanks
ABBV: Key data for lutikizumab, RINVOQ, and IBD combos will drive next-gen immunology advances - TradingView
Where is AbbVie Inc. (ABBV) headed according to the Street? - MSN
AbbVie Deal Crowns 25 Years of Determination; Commercial Leap Is the Next Task, Says Glenn Saldanha - ET Pharma
Where is AbbVie Inc. (ABBV) Headed According to the Street? - Yahoo Finance
Metis Global Partners LLC Has $22.53 Million Stake in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Purchased by Public Sector Pension Investment Board - MarketBeat
Freemont Management S.A. Trims Stake in AbbVie Inc. $ABBV - MarketBeat
AbbVie (NYSE:ABBV) Shares Up 3%What's Next? - MarketBeat
1 reason I'm never selling AbbVie stock - MSN
AbbVie (ABBV) Challenges HHS Over Botox Medicare Price Negotiati - GuruFocus
AbbVie sues Medicare for selecting Botox for price talks (ABBV) - Seeking Alpha
Varma Mutual Pension Insurance Co Has $61 Million Stake in AbbVie Inc. $ABBV - MarketBeat
1 Reason I'm Never Selling AbbVie Stock - The Globe and Mail
Savvy Advisors Inc. Raises Holdings in AbbVie Inc. $ABBV - MarketBeat
Is It Too Late To Consider AbbVie (ABBV) After Its Strong Multi Year Run? - Yahoo Finance
Illinois Municipal Retirement Fund Acquires 19,779 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. (ABBV) Achieves Record Net Sales on Diversified Growth Platform - Yahoo Finance
Atria Investments Inc Decreases Stake in AbbVie Inc. $ABBV - MarketBeat
AbbVie sues US health agency over Botox price controls - WHTC
Abbvie sues US health agency over Botox - whbl.com
AbbVie Sues Medicaid, HHS Over Botox Fair Price Controls - Law360
Evercore ISI Cuts AbbVie Inc. (ABBV) PT, Says Consensus for 2026 and 2027 Still Looks Beatable - Insider Monkey
Evercore ISI cuts AbbVie Inc. (ABBV) PT, says consensus for 2026 and 2027 still looks beatable - MSN
AbbVie Sues HHS Over Selection of Botox for Medicare Price Cuts - Bloomberg Law News
AbbVie sues US Health Department over Botox price controls - marketscreener.com
AbbVie sues US health agency over Botox - marketscreener.com
AbbVie sues U.S. Department of Health and Human Services over selection of Botox for IRA Medicare drug negotiations - marketscreener.com
AbbVie Updates Phase 2 Elezanumab Study in Acute Cervical Spinal Cord Injury: What Investors Should Watch - TipRanks
P/E Ratio Insights for AbbVie - Benzinga
The 5 Most Interesting Analyst Questions From AbbVie's Q4 Earnings Call - Finviz
Rhumbline Advisers Trims Stock Position in AbbVie Inc. $ABBV - MarketBeat
Krilogy Financial LLC Raises Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Stratos Wealth Partners LTD. Has $41.28 Million Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Cibc World Market Inc. Acquires 60,635 Shares of AbbVie Inc. $ABBV - MarketBeat
58,432 Shares in AbbVie Inc. $ABBV Purchased by Caprock Group LLC - MarketBeat
ING Groep NV Purchases 528,196 Shares of AbbVie Inc. $ABBV - MarketBeat
Hepatitis B Treatment Market Size is Projected to Reach USD 7.74 Billion by 2033 Due to the Increasing Disease Management Trends Globally - GlobeNewswire Inc.
The 5 Most Interesting Analyst Questions From AbbVie’s Q4 Earnings Call - Yahoo Finance
AbbVie stock price rises as analysts reset targets and Wall Street waits on delayed jobs data - TechStock²
AbbVie’s $100bn deal aligns drug pricing with domestic manufacturing goals - Yahoo Finance
Here's What Will Drive AbbVie's Top-line Growth in 2026 - The Globe and Mail
Here's Why AbbVie (ABBV) is a Strong Value Stock - Yahoo Finance
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Wealthfront Advisers LLC Has $40.61 Million Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Sold by SVB Wealth LLC - MarketBeat
AbbVie's Botox For Chronic Migraine Leads Pharma SB Program Advertisers 02/10/2026 - MediaPost
The Truth About AbbVie Inc.: Why Everyone Is Suddenly Watching This Pharma Giant - AD HOC NEWS
Finanzdaten der Abbvie Inc-Aktie (ABBV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.50%
0.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):